Disclosure Of Entity's Operating Segments [Text Block]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	20 121 EUR	—	—	—	—	—	—	—	—	—	61 641 EUR	—	—	—	—	—	—	—
Tax expense (income)	— EUR	—	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	—	—	—
Profit (loss) before tax	49 471 EUR	—	—	—	—	—	—	—	—	—	7 570 EUR	—	—	—	—	—	—	—
Profit (loss) from continuing operations	49 471 EUR	—	—	—	—	—	—	—	—	—	7 570 EUR	—	—	—	—	—	—	—
Profit (loss)	49 471 EUR	— EUR	— EUR	49 471 EUR	—	— EUR	— EUR	— EUR	— EUR	— EUR	7 570 EUR	7 570 EUR	—	— EUR	— EUR	— EUR	— EUR	— EUR
Assets	—	—	—	—	111 059 EUR	—	—	—	—	—	—	—	175 187 EUR	—	—	—	—	—
Cash flows from (used in) operating activities	6 896 EUR	—	—	—	—	—	—	—	—	—	32 559 EUR	—	—	—	—	—	—	—
Cash flows from (used in) investing activities	9 200 EUR	—	—	—	—	—	—	—	—	—	20 630 EUR	—	—	—	—	—	—	—
Cash flows from (used in) financing activities	6 008 EUR	—	—	—	—	—	—	—	—	—	1 966 EUR	—	—	—	—	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]